ArticleOncotarget2018
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 83 citations in OpenAlex.
- Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.Nature communications · 2025Trial
- Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer.Hepatology (Baltimore, Md.) · 2019Trial
- BRCA pathogenic variants and response in early TNBC patients treated with neoadjuvant pembrolizumab: outcomes of the BRCAPATH study.Breast cancer (Tokyo, Japan) · 2026Article
- Programmed death ligand-1 (PD-L1) expression in serous ovarian carcinoma with clinicopathological associations.The Indian journal of medical research · 2026Article
- Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer.British journal of cancer · 2026Article
- Durable response to dual immune checkpoint blockade in Lynch syndrome-associated serous ovarian carcinoma: a case report.Frontiers in medicine · 2026Article
- Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.Cancer discovery · 2025Review
- BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.Genes & development · 2025Review
- EML4-ALK-Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review.Clinical case reports · 2025Article
- Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcome.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Article
- Characterization and prognostic impact of ACTBL2-positive tumor-infiltrating leukocytes in epithelial ovarian cancer.Scientific reports · 2023Article
- Machine Learning Quantification of Intraepithelial Tumor-Infiltrating Lymphocytes as a Significant Prognostic Factor in High-Grade Serous Ovarian Carcinomas.International journal of molecular sciences · 2023Article
- Prognostic Significance of Programmed Cell Death Ligand 1 Expression in High-Grade Serous Ovarian Carcinoma: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2023Review
- High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer.Journal of cancer research and clinical oncology · 2023Article
- Article
- Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer.Cancers · 2022Review
- Immunotherapy in Ovarian Cancer.Archivum immunologiae et therapiae experimentalis · 2022Review
- CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.British journal of cancer · 2022Article
- Whole-Genome Sequencing IdentifiesCancers · 2022Article
- Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Checkpoint molecules such as programmed cell death protein-1 (PD-1) and its ligand PD-L1 are critically required for tumor immune escape. The objective of this study was to investigate tumoral
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.